Protocol to establish a lung adenocarcinoma immunotherapy allograft mouse model with FACS and immunofluorescence-based analysis of tumor response

STAR Protoc. 2021 Jun 11;2(2):100595. doi: 10.1016/j.xpro.2021.100595. eCollection 2021 Jun 18.


Anti-PD-1/PD-L1 therapy shows long-term effects in many cancer types, but resistance and relapse remain the main limitations of this therapy. Here, we describe a protocol to evaluate the tumor response to immunotherapy in a mouse lung cancer model. The protocol includes the establishment of the lung cancer mouse model, anti-PD-1 treatment, tumor-infiltrating lymphocyte isolation, immunofluorescence, and flow cytometry analysis. This protocol can also be applied to other cancer types and immunotherapies. For complete details on the use and execution of this protocol, please refer to Yu et al. (2021).

Keywords: Cancer; Cell biology; Cell culture; Cell isolation; Flow cytometry/mass cytometry; Immunology; Microscopy; Model organisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / immunology
  • Adenocarcinoma of Lung / therapy*
  • Animals
  • Cell Separation
  • Disease Models, Animal
  • Flow Cytometry
  • Heterografts
  • Lung Neoplasms / immunology
  • Lung Neoplasms / therapy*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Male
  • Mice
  • Treatment Outcome